AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18240234
Drug: Low-dose corticosteroids
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose corticosteroids (CS) therapy
Trial: 12745095
Drug: Theophylline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (200 mg IV)
Trial: 8403634
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics and/or gentamicin (Septopal) antibiotic beads
Trial: 31428854
Drug: G+1.50 (additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G+1.50 (additional 1500 mL of water)
Trial: 31428854
Drug: G+2.25 (additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G+2.25 (additional 2250 mL of water)
Trial: 31428854
Drug: G+0.50 (additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G+0.50 (additional 500 mL of water)
Trial: 31428854
Drug: G+1.00 (additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G+1.00 (additional 1000 mL of water)
Trial: 31428854
Drug: G+1.50 and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G+1.50 and G+2.25
Trial: 30191972
Drug: Avatrombopag (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avatrombopag (20 mg/day)
Trial: 17000891
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH; 70 U/kg bolus)
Trial: 21960699
Drug: Nebulized levalbuterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized levalbuterol 1.25 mg
Trial: 10763958
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg p.o., b.i.d. for 1 month)
Trial: 8881614
Drug: 0.25% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% hyperbaric bupivacaine (3.2‐3.6 ml, 8‐9 mg)
Trial: 8881614
Drug: 0.25% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% hyperbaric bupivacaine (3.6‐4.0 ml, 9‐10 mg)
Trial: 8881614
Drug: 0.25% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% hyperbaric bupivacaine (4.0‐4.4 ml, 10‐11 mg)
Trial: 8881614
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (3.2‐3.6 ml, 8‐9 mg)
Trial: 1357550
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol (50 micrograms, twice daily)
Trial: 3082733
Drug: Supplementary parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementary parenteral nutrition (200 mg nitrogen per kg per day via central catheter)
Trial: 3082733
Drug: Oral diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diet (40 kcal per kg per day)
Trial: 3082733
Drug: Supplementary parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementary parenteral nutrition
Trial: 20446755
Drug: Long-acting beta2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting beta2 agonists
Trial: 18593773
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone replacement therapy in group A (22 patients)
Trial: 18593773
Drug: Standard replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard replacement therapy without GH in group B (13 patients)
Trial: 18830566
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg IV on admission, followed by 20 mg orally for 7 days
Trial: 18830566
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no gastric acid inhibitor)
Trial: 9757147
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ketoconazole twice a day plus 1.0 mg alprazolam
Trial: 9757147
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ketoconazole twice a day plus 0.25 mg triazolam
Trial: 9757147
Drug: ketoconazole placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoconazole placebo plus 1.0 mg alprazolam
Trial: 9757147
Drug: ketoconazole placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoconazole placebo plus 0.25 mg triazolam
Trial: 7923801
Drug: Naproxene Sodium
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxene Sodium (550 mg) 30 minutes before surgery
Trial: 3410590
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Methyclothiazide with Triamterene (25, 50, 75 mg)
Trial: 27129013
Drug: AZD3839 (1-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3839 (1-300 mg single oral doses)
Trial: 22390677
Drug: Bacopa monnieri
RxNorm normalized name: BACOPA MONNIERI WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacopa monnieri (CDRI08 300 mg/day)
Trial: 22390677
Drug: Pycnogenol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pycnogenol (150 mg/day)
Trial: 19351782
Drug: Nicotrol nasal
RxNorm normalized name: Nicotrol Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotrol nasal spray (actual and expected doses varied)
Trial: 16278986
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (125 mg capsules, twice a day for 10 days)
Trial: 12133084
Drug: Oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam 10 mg (n=56)
Trial: 7771834
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin E for 4 weeks, vitamin C and allopurinol 2 days before and 1 day after coronary artery bypass grafting (Group 1)
Trial: 387216
Drug: Concurrent combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent combination therapy
Trial: 975039
Drug: Single-drug chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-drug chemotherapy administered sequentially
Trial: 23374147
Drug: Total Intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Intravenous Anesthesia with Target-Controlled Infusion (TIVA-TCI)
Trial: 23374147
Drug: Balanced Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced Inhalation Anesthesia (BAL)
Trial: 19095858
Drug: CSE (intrathecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSE (intrathecal bupivacaine 2.5 mg with fentanyl 25 microg)
Trial: 19095858
Drug: EPID (epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPID (epidural bupivacaine 2.5 mg/mL, 3 mL, followed by bupivacaine 1.25 mg/mL, 10 mL with fentanyl 50 microg)
Trial: 11134829
Drug: Paracetamol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (20 mg/kg rectally)
Trial: 9725547
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg cerivastatin daily for 7 days
Trial: 7994829
Drug: Encainide or
RxNorm normalized name: encainide Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encainide or Flecainide (active therapy)
Trial: 7994829
Drug: Moricizine (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine (active therapy)
Trial: 9855480
Drug: Cholecystokinin octapeptide
RxNorm normalized name: Cholecystokinin C-terminal octapeptide
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cholecystokinin octapeptide (CCK-8) infusion (4 ng/kg/min)
Trial: 2680581
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg terbutaline powder by Bricanyl Turbuhaler
Trial: 2680581
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg terbutaline by a conventional jet nebulizer (Pari Inhalierboy)
Trial: 1092245
Drug: Ru‐Vert (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ru‐Vert (25 mg pentylenetetrazol, 12.5 mg pheniramine maleate, 50 mg nictonic acid) at a dosage of two tablets t.i.d.
Trial: 25355774
Drug: Combined antibacterial
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antibacterial and fluoride therapy
Trial: 23916716
Drug: Hyperfractionated radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiotherapy (RT) with cisplatin 20mg/m(2) chemotherapy on 5 consecutive days during weeks 1 and 5 or 6 of RT
Trial: 19349314
Drug: Delta9‐Tetrahydrocannabinol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta9‐Tetrahydrocannabinol (10 mg)
Trial: 15232792
Drug: Special oral
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special oral liquid nutritional supplement (Nepro)
Trial: 15540421
Drug: Methotrexate (MT)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MT) 7.5-10.0 mg/week
Trial: 15540421
Drug: Prednisolone (P)
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone (P) ≥ 10 mg/day + Methotrexate (MT)
Trial: 11137255
Drug: ISCOM vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISCOM vaccines
Trial: 11137255
Drug: Conventional non‐adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional non‐adjuvanted inactivated split virion vaccine
Trial: 1606331
Drug: Ciprofloxacin 1
RxNorm normalized name: ciprofloxacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 1 g/d
Trial: 1606331
Drug: Cimetidine 2400
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine 2400 mg/d
Trial: 1606331
Drug: Ciprofloxacin 1
RxNorm normalized name: ciprofloxacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 1 g/d and Cimetidine 2400 mg/d (combined therapy)
Trial: 1606331
Drug: Drug-free
RxNorm normalized name: HEAD CARE Proactive Health Drug-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free
Trial: 25601762
Drug: Inhaled glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticoids (multiple doses)
Trial: 23284074
Drug: lactate-based low-GDP
RxNorm normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactate-based low-GDP solution
Trial: 23284074
Drug: lactate-based high-GDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactate-based high-GDP solution
Trial: 15780527
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) with estradiol 17‐valerate 2 mg for the first 11 days and estradiol 17‐valerate 2 mg plus ciproterone acetate 1 mg for the next 10 days, administered for 6 months
Trial: 11517122
Drug: Continuous morphine
RxNorm normalized name: morphine sulfate Oral Suspension [MST Continus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous morphine (CM, 10 microg x kg(‐1) x h(‐1)) with three‐hourly placebo boluses
Trial: 11517122
Drug: Intermittent morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent morphine (IM, 30 microg x kg(‐1) every 3 h) with a placebo infusion
Trial: 11517122
Drug: Postoperative plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative plasma concentrations of insulin
Trial: 10197215
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (2 mg)
Trial: 10197215
Drug: Swallowed beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowed beclomethasone dipropionate (2 mg)
Trial: 10197215
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose inhaler with large volume spacer (2 mg beclomethasone dipropionate)
Trial: 3391341
Drug: Sleeping medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleeping medication alone
Trial: 3391341
Drug: Sleeping medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleeping medication with 5.0 mg methscopolamine bromide
Trial: 3391341
Drug: Methscopolamine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methscopolamine administration
Trial: 31571853
Drug: Imidafenacin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidafenacin 0.1 mg
Trial: 28781026
Drug: Low-Dose Statin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose Statin + Armolipid Plus (n=50)
Trial: 28781026
Drug: Low-Dose Statin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose Statin (n=50)
Trial: 21216310
Drug: HIVIS DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIVIS DNA vaccine (arm B)
Trial: 16626544
Drug: rhBNP (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhBNP (1.5 microg/kg bolus intravenous injection followed by 0.0075 microg.kg(‐1).mn(‐1) for the first 3 hours and 0.015‐0.03 microg.kg(‐1).mn(‐1) infusion for following 21 hours)
Trial: 16626544
Drug: NIT (10
RxNorm normalized name: C1 esterase inhibitor 500 unit (10 mL) INTRAVEN KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIT (10 to 100 microg/mn intravenous infusion for 24 hours)
Trial: 7943116
Drug: Butorphanol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (1 to 2 mg hourly on request)
Trial: 7943116
Drug: Fentanyl (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (50 to 100 micrograms hourly on request)
Trial: 7943116
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (Butorphanol and Fentanyl)
Trial: 3605567
Drug: Diazepam 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.25 mg/kg
Trial: 28544222
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy including clarithromycin
Trial: 24973894
Drug: Baclofen at
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baclofen at 80 mg/day
Trial: 21318566
Drug: MDMA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (100 mg oral)
Trial: 21318566
Drug: Methamphetamine (0.42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methamphetamine (0.42 mg/kg oral)
Trial: 19403636
Drug: Dietary Modification
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary Modification intervention (n = 19,541; daily goal: < or =20% of energy as fat, > or =5 servings of vegetables and fruit, and > or =6 servings of grains)
Trial: 10592815
Drug: DTP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP and HibTITER administered concurrently
Trial: 23871120
Drug: Errorless learning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Errorless learning (ELL) and spaced retrieval (SR) cognitive techniques, trained twice a week for 4 weeks
Trial: 11914101
Drug: l-NMMA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-NMMA (3 mg.h(‐1).kg(‐1))
Trial: 1414897
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard diet and drug therapy)
Trial: 31176289
Drug: Current guideline-driven
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current guideline-driven therapy
Trial: 23469629
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for HCV (Pegylated interferon and Ribavirin)
Trial: 23469629
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus Fluvastatin (80 mg/daily)
Trial: 10224805
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 10 mg dydrogesterone twice daily
Trial: 10224805
Drug: Intramuscular HCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular HCG administration 1500 IU every 4 days and 10 mg dydrogesterone twice daily
Trial: 7972382
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of broad-spectrum sunscreens with low SPF
Trial: 7972382
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of broad-spectrum sunscreens with increasing SPF
Trial: 29549104
Drug: 1.8 mg
RxNorm normalized name: menthol 1.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg of 0.1% E2 gel per day
Trial: 29549104
Drug: Transdermal E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2 treatment
Trial: 23186730
Drug: Aerobic dance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic dance classes (2 classes per week) and 30 minutes of daily self-imposed physical activity for 12 weeks
Trial: 21195382
Drug: Oral doxycycline
RxNorm normalized name: doxycycline Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxycycline plus metronidazole
Trial: 21195382
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (observational cohort with additional 75 cases)
Trial: 18499950
Drug: Preoperative education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative education and physical therapy (1 appointment with physiatrist, 2 practical classes with physiotherapist)
Trial: 18499950
Drug: Preoperative education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative education and physical therapy
Trial: 18499950
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preoperative education and physical therapy)
Trial: 16567641
Drug: Cortisone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisone (25 mg) administered orally 1 h before a socio-evaluative stressor
Trial: 16567641
Drug: Cortisol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (10 mg), repeated oral administration 1 h before exposure to a spider photograph
Trial: 14672103
Drug: Wearing a
RxNorm normalized name: Caladryl Clear
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Wearing a lucky garment, taking a test-preparation course, staying up late
Trial: 10746528
Drug: Combined lumbar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined lumbar and sacral plexus block (30 mL lidocaine 1.33% with epinephrine for posterior lumbar plexus block, 10 mL same mixture for parasacral block, and 5 mL lidocaine 1% for iliac crest block)
Trial: 10746528
Drug: Plain bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain bupivacaine spinal anesthesia (3 mL 0.5% plain bupivacaine)
Trial: 3492413
Drug: Sucralfate 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1.0 g qid
Trial: 3492413
Drug: Aspirin 2.5
RxNorm normalized name: aspirin 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 2.5 g
Trial: 30467685
Drug: Combined spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined spironolactone (25 mg/d) plus vitamin E (400 IU/d) for 52 weeks
Trial: 27639137
Drug: Extended-release naproxen
RxNorm normalized name: naproxen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naproxen sodium 660 mg once daily
Trial: 27639137
Drug: Immediate-release naproxen
RxNorm normalized name: naproxen Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release naproxen sodium 220 mg twice daily (440 mg initially, followed by 220 mg 12 hours later)
Trial: 18363528
Drug: Medication reconciliation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reconciliation program (113 patients)
Trial: 15821181
Drug: Soy oil
RxNorm normalized name: Hydrogenated soy oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy oil (2 g/d)
Trial: 10716040
Drug: Phenylpropanolamine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine administered in combination with chlorpheniramine maleate at 2200 hours
Trial: 10716040
Drug: Phenylpropanolamine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine administered in combination with chlorpheniramine maleate at 1000 hours
Trial: 8538480
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oestradiol valerate (days 1‐21) + 1 mg cyproterone acetate (days 12‐21)
Trial: 8538480
Drug: Transdermal 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17 beta‐oestradiol (50 micrograms twice weekly during three weeks) + 20 mg dydrogesterone (days 12‐21)